Vistagen Therapeutics (VTGN) director files initial Form 3 ownership report

Rhea-AI Filing Summary

Vistagen Therapeutics, Inc. filed a Form 3 initial statement of beneficial ownership for Douglas J Williamson, who is identified as a director of the company. The filing reports no transactions and does not list any equity holdings or derivative positions for him.

Key Terms

reporting person, director, ten percent owner

3 terms

reporting person regulatory

"The reportingPersons section identifies Douglas J Williamson as a reporting person"

director regulatory

"is_director is marked as 1, showing Williamson serves as a director"

ten percent owner regulatory

"is_ten_percent_owner is 0, indicating he is not a ten percent owner"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/31/2026 - 08:53 AM Accepted by SEC EDGAR 07/31/2026 - 08:53 AM Learn about SEC filing dates

FAQ

What does Vistagen Therapeutics (VTGN) disclose in this Form 3 for Douglas J Williamson?

Vistagen Therapeutics’ Form 3 identifies Douglas J Williamson as a director and reports no transactions or listed holdings. It is an initial statement of beneficial ownership, indicating his reporting status as an insider.

Does the VTGN Form 3 for Douglas J Williamson report any share transactions?

No. The Form 3 for Douglas J Williamson shows no reported transactions, with the transaction list empty. The summary data also indicates zero buy, sell, or exercise activity associated with this filing.

Are any stock or option holdings reported for Douglas J Williamson in VTGN’s Form 3?

No. The filing shows zero holding entries and an empty derivative summary, meaning no specific equity or derivative positions are listed for Douglas J Williamson in this initial ownership report.

What insider role is reported for Douglas J Williamson in Vistagen Therapeutics (VTGN)?

Douglas J Williamson is reported as a director of Vistagen Therapeutics, Inc. The Form 3 flags him as a director and not as a ten percent owner or officer, establishing his status as a reporting person.

Does the VTGN Form 3 mention any Rule 10b5-1 trading plan for Douglas J Williamson?

No. The Form 3’s Rule 10b5-1 plan indicator is null, and there is no transaction activity or footnote language describing trades under a pre-arranged 10b5-1 trading plan for Douglas J Williamson.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Williamson Douglas J

(Last) (First) (Middle)

C/O VISTAGEN THERAPEUTICS, INC.

343 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/29/2026

3. Issuer Name and Ticker or Trading Symbol
Vistagen Therapeutics, Inc. [ VTGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Douglas J. Williamson	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)